Amyotrophic Lateral Sclerosis Stocks List

Recent Signals

Date Stock Signal Type
2021-05-06 AQST New 52 Week Low Weakness
2021-05-06 AQST Expansion Breakdown Bearish Swing Setup
2021-05-06 AQST Stochastic Reached Oversold Weakness
2021-05-06 AQST New 52 Week Closing Low Bearish
2021-05-06 BCLI Bollinger Band Squeeze Range Contraction
2021-05-06 BCLI Doji - Bullish? Reversal
2021-05-06 CYTK Fell Below 50 DMA Bearish
2021-05-06 CYTK NR7 Range Contraction
2021-05-06 CYTK Stochastic Reached Oversold Weakness
2021-05-06 DNLI MACD Bearish Signal Line Cross Bearish
2021-05-06 LBPH NR7 Range Contraction
2021-05-06 LBPH Narrow Range Bar Range Contraction
2021-05-06 MITO Crossed Above 20 DMA Bullish
2021-05-06 MITO Crossed Above 50 DMA Bullish
2021-05-06 MITO Crossed Above 200 DMA Bullish
2021-05-06 MITO Volume Surge Other
2021-05-06 MITO Wide Range Bar Range Expansion
2021-05-06 MITO Gilligan's Island Sell Setup Bearish Swing Setup
2021-05-06 MITO Pocket Pivot Bullish Swing Setup
2021-05-06 MYO Pocket Pivot Bullish Swing Setup
2021-05-06 PRTA NR7-2 Range Contraction
2021-05-06 PRTA NR7 Range Contraction
2021-05-06 PRTA Fell Below 50 DMA Bearish
2021-05-06 YMTX New 52 Week Low Weakness
2021-05-06 YMTX New 52 Week Closing Low Bearish
2021-05-06 YMTX Expansion Breakdown Bearish Swing Setup
2021-05-06 YMTX Lower Bollinger Band Walk Weakness
2021-05-06 YMTX New Downtrend Bearish

Recent News for Amyotrophic Lateral Sclerosis Stocks

Date Stock Title
May 7 CYTK Cytokinetics' (CYTK) CEO Robert Blum on Q1 2021 Results - Earnings Call Transcript
May 6 CYTK Cytokinetics (CYTK) Reports Q1 Loss, Lags Revenue Estimates
May 6 CYTK Cytokinetics EPS misses by $0.06, misses on revenue
May 6 CYTK Cytokinetics Reports First Quarter 2021 Financial Results
May 6 MITO Stealth BioTherapeutics skyrockets on data for elamipretide study
May 6 CYTK Cytokinetics Announces Start of Open-Label Extension Study for Patients Completing REDWOOD-HCM
May 5 MYO Myomo, Inc. (MYO) Reports Q1 Loss, Tops Revenue Estimates
May 5 MYO Myomo reports Q1 results
May 5 MITO Stealth BioTherapeutics Showcases Data for Elamipretide in Dry Age-Related Macular Degeneration at the 2021 ARVO Annual Meeting
May 5 MYO Myomo Reports First Quarter 2021 Financial Results
May 5 CYTK Cytokinetics to Hold Annual Meeting of Stockholders
May 5 AQST Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2021 Results - Earnings Call Transcript
May 5 CYTK Shareholders Will Probably Hold Off On Increasing Cytokinetics, Incorporated's (NASDAQ:CYTK) CEO Compensation For The Time Being
May 5 AQST Aquestive Therapeutics EPS beats by $0.01, beats on revenue
May 5 AQST Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
May 4 AQST Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
May 4 PRTA Prothena to Report First Quarter 2021 Financial Results on May 11th
May 4 DNLI Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
May 4 CYTK Cytokinetics' Cohort 3 of REDWOOD-HCM trial is open to enrollment
May 4 YMTX Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021
Related Industries: Biotechnology Medical Devices

Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND) or Lou Gehrig's disease, is a specific disease which causes the death of neurons controlling voluntary muscles. Some also use the term motor neuron disease for a group of conditions of which ALS is the most common. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. It may begin with weakness in the arms or legs, or with difficulty speaking or swallowing. About half of people develop at least mild difficulties with thinking and behavior and most people experience pain. Most eventually lose the ability to walk, use their hands, speak, swallow, and breathe.The cause is not known in 90% to 95% of cases, but is believed to involve both genetic and environmental factors. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.No cure for ALS is known. The goal of treatment is to improve symptoms. A medication called riluzole may extend life by about two to three months. Non-invasive ventilation may result in both improved quality and length of life. Mechanical ventilation can prolong survival but does not stop disease progression. A feeding tube may help. The disease can affect people of any age, but usually starts around the age of 60 and in inherited cases around the age of 50. The average survival from onset to death is two to four years, though this can vary. About 10% survive longer than 10 years. Most die from respiratory failure. The disease affects about two people per 100,000 per year worldwide.Descriptions of the disease date back to at least 1824 by Charles Bell. In 1869, the connection between the symptoms and the underlying neurological problems was first described by Jean-Martin Charcot, who in 1874 began using the term amyotrophic lateral sclerosis. It became well known in the United States in the 20th century when in 1939 it affected the baseball player Lou Gehrig and later worldwide following the 1963 diagnosis of cosmologist Stephen Hawking. The first ALS gene was discovered in 1993 while the first animal model was developed in 1994. In 2014, videos of the Ice Bucket Challenge went viral on the Internet and increased public awareness of the condition.

More about Amyotrophic Lateral Sclerosis
Browse All Tags